Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Theravance Biopharma (NASDAQ:TBPH) is the #1 top healthcare stock out of 1106 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Theravance Biopharma (NASDAQ:TBPH) is: Value: B, Growth: A, Momentum: C, Sentiment: B, Safety: D, Financials: A, and AI: C.

Theravance Biopharma (NASDAQ:TBPH) has a Due Diligence Score of 39, which is 14 points higher than the healthcare sector average of 25. It passed 12 out of 33 due diligence checks and has average fundamentals. Theravance Biopharma has seen its stock return 70.81% over the past year, overperforming other healthcare stocks by 113 percentage points.

Theravance Biopharma has an average 1 year price target of $25.67, an upside of 85.05% from Theravance Biopharma's current stock price of $13.87.

Theravance Biopharma stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Theravance Biopharma, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Embecta (NASDAQ:EMBC) is the #2 top healthcare stock out of 1106 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Embecta (NASDAQ:EMBC) is: Value: A, Growth: A, Momentum: C, Sentiment: B, Safety: D, Financials: A, and AI: C.

Embecta (NASDAQ:EMBC) has a Due Diligence Score of 35, which is 10 points higher than the healthcare sector average of 25. It passed 12 out of 38 due diligence checks and has average fundamentals. Embecta has seen its stock lose -8.44% over the past year, overperforming other healthcare stocks by 33 percentage points.

Embecta has an average 1 year price target of $18.50, an upside of 22.68% from Embecta's current stock price of $15.08.

Embecta stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Embecta, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Livanova (NASDAQ:LIVN) is the #3 top healthcare stock out of 1106 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Livanova (NASDAQ:LIVN) is: Value: B, Growth: A, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: A.

Livanova (NASDAQ:LIVN) has a Due Diligence Score of 17, which is -8 points lower than the healthcare sector average of 25. Although this number is below the industry average, our proven quant model rates LIVN as a "A".It passed 5 out of 33 due diligence checks and has weak fundamentals. Livanova has seen its stock return 12.58% over the past year, overperforming other healthcare stocks by 54 percentage points.

Livanova has an average 1 year price target of $60.75, an upside of 10.6% from Livanova's current stock price of $54.93.

Livanova stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Livanova, 0% have issued a Strong Buy rating, 75% have issued a Buy, 25% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 72 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Essa Pharma (NASDAQ:EPIX) has an annual dividend yield of 876.18%, which is 863 percentage points higher than the healthcare sector average of 13.44%.

Essa Pharma's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 15.16%, which is 2 percentage points higher than the healthcare sector average of 13.44%. Select Medical Holdings's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Select Medical Holdings's dividend has not shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 35.1% indicates that its high dividend yield is sustainable for the long-term.

Cryo Cell International (NYSEMKT:CCEL) has an annual dividend yield of 8.95%, which is -4 percentage points lower than the healthcare sector average of 13.44%.

Cryo Cell International's dividend payout ratio of -2,166.7% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were up 0.02% in the last day, and down -1.69% over the last week. Co Diagnostics was the among the top gainers in the healthcare sector, gaining 81.02% yesterday.

Co-Diagnostics shares are trading lower after the company announced a $3.8 million registered direct offering of 9.619 million shares at a price of $0.40 per share.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -16.69% in the past year. It has overperformed other stocks in the healthcare sector by 25 percentage points.

Embecta (NASDAQ:EMBC) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 41 points higher than the healthcare sector average of 16. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -8.44% in the past year. It has overperformed other stocks in the healthcare sector by 33 percentage points.

Puma Biotechnology (NASDAQ:PBYI) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 27 points higher than the healthcare sector average of 16. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 79.37% in the past year. It has overperformed other stocks in the healthcare sector by 121 percentage points.

49.94% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 41.6% over the next year.

4.61% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.65% of healthcare stocks are rated B (Buy), 45.74% are rated C (Hold), 26.36% are rated D (Sell), and 10.64% are rated F (Strong Sell).